MedTrace Logo

OLP-1002 is Being Studied in the Treatment of Pain.

NCT03760913 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2021-08-26

Study results available
· View outcomes & findings →

Summary

The primary objective of the study is to assess the safety and tolerability of single and multiple subcutaneous doses of OLP-1002 in healthy subjects.

Conditions

Interventions

DRUG

OLP-1002 (Test): Part A, Single Ascending Dose

Subcutaneous Injection: 30 ng, 120 ng, 400 ng, 1.2 µg, 3 µg, 6 µg, 12 µg, 20 µg, 40 μg, 80 μg, 160 μg

DRUG

OLP-1002 (Test): Part B, Multiple Ascending Dose

Subcutaneous Injection: 5 x 2 μg, 5 x 5 μg, 5 x 10 μg, 5 x 20 μg, 5 x 40 μg, 5 x 80 μg

OTHER

Placebo: Placebo Part A, Single Ascending Dose

Subcutaneous Injection: Placebo

OTHER

Placebo: Placebo Part B, Multiple Ascending Dose

Subcutaneous Injection: Placebo x 5

Sponsors & Collaborators

  • OliPass Corporation

    lead INDUSTRY

Principal Investigators

  • Firas Almazedi, MBChB, MSc, CPI, DipPharmMed · Covance CRU Leeds

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-11-21
Primary Completion
2020-10-16
Completion
2020-10-16

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03760913 on ClinicalTrials.gov